

Cases from the Community: Investigators Provide Their Perspectives on the Practice Implications of Emerging Clinical Research

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III ExteNET trial, which investigated neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer (BC), reported a 2% invasive disease-free survival benefit among patients with HER2-positive disease and a 6% benefit in _____ disease.
 - Hormone receptor-positive, HER2-positive
 - Hormone receptor-negative, HER2-positive
 - Neither a nor b
- The ongoing Phase III _____ study randomly assigns patients with HER2-positive BC who have residual disease after neoadjuvant therapy to trastuzumab or T-DM1.
 - RxPONDER
 - KATHERINE
 - KRISTINE
- The aim of the MINDACT trial, for which initial results were recently reported, was to evaluate the benefit of genomic testing with the _____ in addition to standard clinicopathologic criteria for patients with early BC and 0 to 3 positive nodes who may safely forgo chemotherapy without compromising outcomes.
 - Breast Cancer Index
 - 21-gene signature
 - 70-gene signature
- The Phase III PALOMA-2 trial, comparing palbociclib with letrozole to letrozole alone for patients with ER-positive/HER2-negative advanced BC who had not previously received systemic therapy _____ the significant clinical benefit and safety of palbociclib/letrozole that was previously demonstrated in the PALOMA-1 trial.
 - Confirmed
 - Refuted
- Activating mutations in the ESR1 gene are associated with resistance to standard endocrine therapies, particularly among patients who are receiving aromatase inhibitors.
 - True
 - False
- The Phase III PHEREXA trial, evaluating trastuzumab/capecitabine with or without pertuzumab after disease progression on trastuzumab-based therapy for HER2-positive metastatic BC, did not demonstrate a statistically significant improvement in the primary endpoint of _____ with the addition of pertuzumab.
 - Median overall survival
 - Median progression-free survival
 - Overall response rate
- Data from the primary analysis of the Phase II PERTAIN study of pertuzumab, trastuzumab and anastrozole versus trastuzumab/anastrozole for patients with hormone receptor-positive, HER2-positive advanced BC indicated that the combination of pertuzumab, trastuzumab and anastrozole was _____ compared to trastuzumab/anastrozole alone.
 - Inferior
 - Superior
 - Neither a nor b; results were similar on both arms
- The Phase III EMBRACA trial is evaluating _____ for patients with BRCA mutation-positive locally advanced or metastatic BC.
 - Veliparib
 - Niraparib
 - Talazoparib
 - Olaparib

Cases from the Community: Investigators Provide Their Perspectives on the Practice Implications of Emerging Clinical Research

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The results of the GeparSepto (GBG 69) trial, evaluating neoadjuvant chemotherapy with weekly nanoparticle albumin-bound (*nab*) paclitaxel versus solvent-based paclitaxel followed by an anthracycline and cyclophosphamide in patients with early BC demonstrated a statistically significant improvement in _____ with *nab* paclitaxel.
- a. Sensory neuropathy
 - b. Pathologic complete response
 - c. Both a and b
10. Early Phase I trials have demonstrated that the anti-PD-1 agent pembrolizumab and the anti-PD-L1 agent atezolizumab yield response rates of _____ for patients with metastatic triple-negative BC.
- a. 18% to 20%
 - b. 25% to 30%
 - c. 40% to 50%